glp 1 drugs and ulcerative colitis Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, therapeutic potential Ulcerative colitis and GLP-1 medications

Neurogastroenterol Motil 2017;29

Specifically, the 6,000-patient study found no increased risk for cardiovascular death, heart attack, stroke, unstable angina or heart failure in people with type 2 diabetes who had recently experienced acute coronary syndrome (ACS) events

The authors also stressed that the use of these medications should be viewed in a broader health context, including issues such as access, affordability, and insurance coverage, so that existing health inequities are not made worse

Ozempic accounted for 2% of this amount

Posch MG, Walther N, Ferrannini E, Powell DR, Banks P, Wason S, Dahmen R

Neither treatment is automatically better than the other